These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7552714)

  • 1. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1.
    Aertgeerts K; De Bondt HL; De Ranter CJ; Declerck PJ
    Nat Struct Biol; 1995 Oct; 2(10):891-7. PubMed ID: 7552714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
    Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
    J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
    Gils A; Knockaert I; Declerck PJ
    Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.
    Sharp AM; Stein PE; Pannu NS; Carrell RW; Berkenpas MB; Ginsburg D; Lawrence DA; Read RJ
    Structure; 1999 Feb; 7(2):111-8. PubMed ID: 10368279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein conformational change delayed by steric hindrance from an N-linked glycan.
    Bager R; Johansen JS; Jensen JK; Stensballe A; Jendroszek A; Buxbom L; Sørensen HP; Andreasen PA
    J Mol Biol; 2013 Aug; 425(16):2867-77. PubMed ID: 23702291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model of the reactive form of plasminogen activator inhibitor-1.
    Aertgeerts K; De Bondt HL; De Ranter C; Declerck PJ
    J Struct Biol; 1994; 113(3):239-45. PubMed ID: 7734247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
    Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
    Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
    Gils A; Declerck PJ
    J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for serpin inhibitor activity.
    Wright HT; Scarsdale JN
    Proteins; 1995 Jul; 22(3):210-25. PubMed ID: 7479695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q; Shaltiel S
    BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1.
    Gils A; Lu J; Aertgeerts K; Knockaert I; Declerck PJ
    FEBS Lett; 1997 Sep; 415(2):192-5. PubMed ID: 9350994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
    Audenaert AM; Knockaert I; Collen D; Declerck PJ
    J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.
    Krüger P; Verheyden S; Declerck PJ; Engelborghs Y
    Protein Sci; 2001 Apr; 10(4):798-808. PubMed ID: 11274471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1.
    Wardell MR; Chang WS; Bruce D; Skinner R; Lesk AM; Carrell RW
    Biochemistry; 1997 Oct; 36(42):13133-42. PubMed ID: 9335576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural factors affecting the choice between latency transition and polymerization in inhibitory serpins.
    Yi JY; Im H
    Protein Sci; 2007 May; 16(5):833-41. PubMed ID: 17400919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
    Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
    Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering of conformations of plasminogen activator inhibitor-1. A crucial role of beta-strand 5A residues in the transition of active form to latent and substrate forms.
    Kirkegaard T; Jensen S; Schousboe SL; Petersen HH; Egelund R; Andreasen PA; Rodenburg KW
    Eur J Biochem; 1999 Jul; 263(2):577-86. PubMed ID: 10406969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.